These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30306872)

  • 1. Combiphore (Structure and Ligand Based Pharmacophore) - Approach for the Design of GPR40 Modulators in the Management of Diabetes.
    Gajjar KA; Gajjar AK
    Curr Drug Discov Technol; 2020; 17(2):233-247. PubMed ID: 30306872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CoMFA, CoMSIA and HQSAR Analysis of 3-aryl-3-ethoxypropanoic Acid Derivatives as GPR40 Modulators.
    Gajjar KA; Gajjar AK
    Curr Drug Discov Technol; 2020; 17(1):100-118. PubMed ID: 30160214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.
    Srivastava A; Yano J; Hirozane Y; Kefala G; Gruswitz F; Snell G; Lane W; Ivetac A; Aertgeerts K; Nguyen J; Jennings A; Okada K
    Nature; 2014 Sep; 513(7516):124-7. PubMed ID: 25043059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-based pharmacophore detection, screening of potential gliptins and docking studies to get effective antidiabetic agents.
    Agrawal R; Jain P; Dikshit SN
    Comb Chem High Throughput Screen; 2012 Dec; 15(10):849-76. PubMed ID: 23140189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for GPR40 allosteric agonism and incretin stimulation.
    Ho JD; Chau B; Rodgers L; Lu F; Wilbur KL; Otto KA; Chen Y; Song M; Riley JP; Yang HC; Reynolds NA; Kahl SD; Lewis AP; Groshong C; Madsen RE; Conners K; Lineswala JP; Gheyi T; Saflor MD; Lee MR; Benach J; Baker KA; Montrose-Rafizadeh C; Genin MJ; Miller AR; Hamdouchi C
    Nat Commun; 2018 Apr; 9(1):1645. PubMed ID: 29695780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel G-protein-coupled receptor 40 (GPR40) agonists by hybrid
    Nath V; Ahuja R; Kumar V
    J Biomol Struct Dyn; 2019 Sep; 37(14):3764-3787. PubMed ID: 30252605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
    Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
    J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore-guided repurposing of fibrates and retinoids as GPR40 allosteric ligands with activity on insulin release.
    Cione E; Caroleo MC; Kagechika H; Manetti F
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):377-383. PubMed ID: 33525941
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Vink G; Nebel JC; Wren SP
    Future Med Chem; 2021 Apr; 13(8):691-700. PubMed ID: 33715419
    [No Abstract]   [Full Text] [Related]  

  • 11. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
    Musoev A; Numonov S; You Z; Gao H
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
    Mancini AD; Poitout V
    Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
    Jana S; Singh SK
    J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore modeling, comprehensive 3D-QSAR, and binding mode analysis of TGR5 agonists.
    Sindhu T; Srinivasan P
    J Recept Signal Transduct Res; 2017 Apr; 37(2):109-123. PubMed ID: 27267434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel potent GPR40 full agonist.
    Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
    Burant CF
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S175-9. PubMed ID: 23882043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR Based Pharmacophore Modeling and Virtual Screening for Identification of Novel G Protein-Coupled Receptor40 Agonists.
    Lu P; Wang Y; Ouyang P; She J; He M
    Curr Comput Aided Drug Des; 2015; 11(1):51-6. PubMed ID: 26022066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes.
    Choi YJ; Shin D; Lee JY
    Arch Pharm Res; 2014 Apr; 37(4):435-9. PubMed ID: 24234912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.